(function() { var x="https://ads.ehealthcaresolutions.com/c/?"+Math.random()*1e16; var y=document.createElement("script");y.type="text/javascript";y.async=true;y.src=x; var z=document.getElementsByTagName("script")[0]; z.parentNode.insertBefore(y, z); })();
Tuesday , June 19 2018
Home / Therapies / SGLT-2 Therapy Center (page 21)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Treatment with Ipragliflozin + Metformin

Combination well-tolerated in patients with type 2 diabetes…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug canagliflozin by increasing urinary excretion …

Read More »

History of the SGLT2 Inhibitor Drug Class

Phuong Nguyen, PharmD Candidate, LECOM College of Pharmacy Remarkable as it might sound, the SGLT2 inhibitor drug class arguably dates back 178 years. In 1835, French chemists first isolated a substance known as phlorizin from the bark of apple trees, and in 1886, German physician and early diabetes pioneer Joseph von …

Read More »

The Expansion of the SGLT-2 Inhibitor Market

What’s New on the Horizon? Heather Good, Doctor of Pharmacy, Candidate University of Florida Sodium-glucose co-transporter 2 (SGLT2) inhibitors, the first drugs to actually eliminate glucose from the body, are paving the way for a new wave of diabetes treatment options. Canagliflozin (Invokana®) took the U.S. market by storm when …

Read More »

SGLT2 Inhibitors and Beta-Cell Preservation

Phuong Nguyen, Doctor of Pharmacy Candidate, LECOM, College of Pharmacy Studies investigating both mice and humans have shown that chronic hyperglycemia may shift the balance of B-cell proliferation and apoptosis toward cell death, consequently resulting in B-cell deficiency and impaired insulin secretion. Idris and Donnelly (2009) studied the effect of …

Read More »

Prescription Coverage for SGLT2 inhibitors

Here’s out most recent list of insurance covereage. The cash price for 1 month of Invokana is $315.72. Current actual coverage is: RXE United and other discount cards are approximately $268. PSN Commercial calls it non-formulary and charges a $100 co-pay. AARP-United Health will allow the first fill with a $95 …

Read More »

Dapagliflozin Resubmitted to FDA

The FDA has acknowledged receipt of a resubmission of the new drug application (NDA) for dapagliflozin, an SGLT-2 inhibitor for the treatment of type 2 diabetes…. Astra Zeneca and Bristol-Myers Squibb (BMS) have announced that the agency has issued a new Prescription Drug User Fee Act goal date of January …

Read More »

AACE Presentations of SGLT-2 Inhibitor Data

David Joffe, BSPharm, CDE, Editor-in-chief, Diabetes In Control Lauren Self, University of Florida College of Pharmacy, PharmD Candidate When the finest, most talented endocrinologists get together for a conference, you can bet that there will be a lot of great information on the latest in diabetes care. This year it …

Read More »